Recombinant Human UCH-L1/PGP9.5 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 6007-CY

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
6007-CY-020
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

E. coli

Accession #

P09936

Structure / Form

Monomer

Conjugate

Unconjugated

Applications

Enzyme Activity

View all UCH-L1/PGP9.5 Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human UCH-L1/PGP9.5 protein
Gln2-Ala223 with an N-terminal Met and 6-His tag

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

26 kDa

SDS-PAGE

27 kDa, reducing conditions

Activity

Measured by the hydrolysis of Ubiquitin-AMC.
The specific activity is >100 pmol/min/μg, as measured under the described conditions.

Formulation, Preparation and Storage

6007-CY
Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, Glycerol and DTT.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.

Background: UCH-L1/PGP9.5

Deubiquitination is a critical regulatory process in the ubiquitin-proteasome pathway (1). Ubiquitin C-terminal hydrolases (UCHs) are a family of cysteine proteases that catalyze the hydrolysis of a peptide bond at the C-terminal glycine of ubiquitin. Members of the UCH family have been implicated in a number of human diseases, including neurodegenerative diseases and cancers (2). Mutations of the UCH-L1 gene and alterations of the protein activity have been found to be associated with several neurodegenerative disorders, including Parkinson’s, Huntington’s and Alzheimer’s diseases (3).  It is also implicated in cancer tumorigenesis, including lung, breast, liver, kidney, colorectal and ovarian cancers (4-8). UCH-L1 is thought to be a tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.

References

  1. Wing, S. (2003) Int. J. Biochem. Cell Biol. 35:590.
  2. Ventii, KH and Wilkinson, KD (2008) Biochem. J. 414:161.
  3. Gong, B. and Leznik, E. (2007) Drug News Perspect. 20:365.
  4. Kim, H. et al. (2009) Oncogene 28:117.
  5. Wang, W. et al. (2008) Int. J. Oncol. 33:1037.
  6. Yu, J. et al. (2008) Hepatology 48:508.
  7. Kagara, I. et al. (2008) J. Urol. 180:343.
  8. Okochi-Takada, E. et al. (2006) Int. J. Cancer 119:1338.

Long Name

Ubiquitin C-terminal Hydrolase L1

Alternate Names

PARK5, PGP9.5, UCHL1

Entrez Gene IDs

7345 (Human); 22223 (Mouse)

Gene Symbol

UCHL1

UniProt

P09936 (Human)

Additional UCH-L1/PGP9.5 Products

Product Documents for Recombinant Human UCH-L1/PGP9.5 Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human UCH-L1/PGP9.5 Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.